FDA Approves Accord BioPharma’s IMULDOSA for Treating Chronic Inflammatory Conditions
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., which focuses on oncology, immunology, and critical care therapies, has announced the FDA approval of IMULDOSA (uste ...
USA: Expectations of Psoriasis patients (Patient outcome study 2021-22)
[vc_row][vc_column][vc_custom_heading text="USA: Expectations of Psoriasis patients (Patient outcome study 2021-22)" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_ro ...